STOCK TITAN

Gilead Sciences, Inc. - GILD STOCK NEWS

Welcome to our dedicated news page for Gilead Sciences (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gilead Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gilead Sciences's position in the market.

Rhea-AI Summary
Gilead Sciences executives to speak at investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
conferences
-
Rhea-AI Summary
Gilead Sciences' Pharmaceutical Development and Manufacturing (PDM) team plays a key role in creating and delivering medicines. They ensure an adequate and high-quality supply during clinical trials and after product approval. PDM's innovation in manufacturing technology contributes to Gilead's success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
-
Rhea-AI Summary
FDA places partial clinical hold on new patients in Gilead's magrolimab AML studies
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
Rhea-AI Summary
Gilead Sciences and Meharry Medical College publish a supplemental issue detailing the impact of the Gilead COMPASS Initiative in addressing the HIV epidemic in the Southern United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
-
Rhea-AI Summary
Gilead Sciences is partnering with clinicians to develop advanced and accessible therapies for children living with HIV. Currently, only 54% of children with HIV are on antiretroviral therapy compared to 74% of adults. Gilead aims to close this treatment gap by developing innovative therapies and improving medication accessibility. They have opened the global Pediatric Centre of Excellence in Dublin to coordinate pediatric clinical trials and are collaborating to create dispersible medications for children. Long-acting injectable medications are also being explored as a potential solution. Closing the treatment gap for children is crucial in ending the HIV epidemic.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
none
-
Rhea-AI Summary
GILD: Gilead Sciences and Tentarix Biotherapeutics Collaborate to Develop Novel Therapies for Oncology and Inflammatory Diseases, Gilead to Acquire Exclusive Rights. Tentarix to Receive $66 Million in Upfront Payments and Equity Investment from Gilead
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
none
Rhea-AI Summary
Gilead Sciences (GILD) announces a new educational initiative to raise awareness about HIV prevention and treatment. The company will provide resources and support for at-risk communities, emphasizing the importance of early intervention and access to care. This initiative aligns with Gilead's commitment to public health and social responsibility, showcasing their leadership in the pharmaceutical industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
-
Rhea-AI Summary
Gilead Sciences Inc. announces a $6 million grant program to support health equity for Australian and Canadian Indigenous communities. The program aims to address disparities in health outcomes related to HIV and viral hepatitis. Gilead is partnering with Indigenous-led organizations to fund culturally appropriate solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Gilead Sciences receives European Commission approval for Trodelvy as a monotherapy for the treatment of HR-positive, HER2-negative breast cancer. The approval is based on the Phase 3 TROPiCS-02 study, which showed a statistically significant overall survival benefit and a reduction in disease progression or death. Trodelvy could replace standard chemotherapy and provide a new treatment option for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
Gilead Sciences, Inc.

Nasdaq:GILD

GILD Rankings

GILD Stock Data

84.88B
1.24B
0.09%
88.37%
1.81%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Foster City

About GILD

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.